Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 375

1.

Evaluation of the Synergy of Ceftazidime-Avibactam in combination with Meropenem, Amikacin, Aztreonam, Colistin and Fosfomycin Against Well Characterized Multi-Drug Resistant K. pneumoniae and P. aeruginosa.

Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M, Rybak MJ.

Antimicrob Agents Chemother. 2019 Jun 10. pii: AAC.00779-19. doi: 10.1128/AAC.00779-19. [Epub ahead of print]

PMID:
31182535
2.

Trends in and predictors of carbapenem consumption across North American hospitals: results from a multi-center survey by the MAD-ID Research Network.

Rhodes NJ, Wagner JL, Davis SL, Bosso JA, Goff DA, Rybak MJ, Scheetz MH; MAD-ID Research Network.

Antimicrob Agents Chemother. 2019 May 6. pii: AAC.00327-19. doi: 10.1128/AAC.00327-19. [Epub ahead of print]

PMID:
31061154
3.

Efficacy and safety of tedizolid phosphate versus linezolid in a randomized Phase 3 trial in patients with acute bacterial skin and skin structure infection.

Lv X, Alder J, Li L, O'Riordan W, Rybak MJ, Ye H, Zhang R, Zhang Z, Zhu X, Wilcox MH.

Antimicrob Agents Chemother. 2019 Apr 15. pii: AAC.02252-18. doi: 10.1128/AAC.02252-18. [Epub ahead of print]

4.

The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin.

Zasowski EJ, Trinh TD, Atwan SM, Merzlyakova M, Langf AM, Bhatia S, Rybak MJ.

Open Forum Infect Dis. 2019 Apr 3;6(4):ofz079. doi: 10.1093/ofid/ofz079. eCollection 2019 Apr.

5.

Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model.

Kebriaei R, Rice SA, Stamper KC, Seepersaud R, Garcia-de-la-Maria C, Mishra NN, Miro JM, Arias CA, Tran TT, Sullam PM, Bayer AS, Rybak MJ.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00386-19. doi: 10.1128/AAC.00386-19. Print 2019 Jun.

PMID:
30962347
6.

Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.

Corey GR, McKinnell JA, Rybak MJ.

Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S191-S192. doi: 10.1093/cid/ciy1089. No abstract available.

7.

Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus.

Claeys KC, Zasowski EJ, Trinh TD, Casapao AM, Pogue JM, Bhatia N, Mynatt RP, Wilson SS, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado G, Giuliano CA, Takla R, Rieck C, Johnson LB, Murray KP, Gordon J, Reyes K, Hartman P, Davis SL, Rybak MJ.

Infect Dis Ther. 2019 Jun;8(2):199-208. doi: 10.1007/s40121-019-0242-5. Epub 2019 Mar 27.

8.

Teaching an Old Class New Tricks: A Novel Semi-Synthetic Aminoglycoside, Plazomicin.

Abdul-Mutakabbir JC, Kebriaei R, Jorgensen SCJ, Rybak MJ.

Infect Dis Ther. 2019 Jun;8(2):155-170. doi: 10.1007/s40121-019-0239-0. Epub 2019 Mar 9. Review.

9.

Bactericidal activity of ceftaroline, vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus isolates from cancer patients.

Rolston KVI, Jamal M, Nesher L, Raad I, Rice SA, Rybak MJ, Prince RA.

J Glob Antimicrob Resist. 2019 Mar 5;17:16-18. doi: 10.1016/j.jgar.2019.02.018. [Epub ahead of print] No abstract available.

PMID:
30844496
10.

Diagnostic Stewardship: A Clinical Decision Rule for Blood Cultures in Community-Onset Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft Tissue Infections.

Jorgensen SCJ, Lagnf AM, Bhatia S, Singh NB, Shammout LK, Davis SL, Rybak MJ.

Infect Dis Ther. 2019 Jun;8(2):229-242. doi: 10.1007/s40121-019-0238-1. Epub 2019 Feb 19.

11.

A new simplified predictive model for mortality in methicillin-resistant Staphylococcus aureus bacteremia.

Jorgensen SCJ, Lagnf AM, Bhatia S, Rybak MJ.

Eur J Clin Microbiol Infect Dis. 2019 May;38(5):843-850. doi: 10.1007/s10096-018-03464-0. Epub 2019 Feb 8.

PMID:
30734879
12.

Reply to Koehler, et al.

Beganovic M, Luther MK, Rice LB, Arias CA, Rybak MJ, LaPlante KL.

Clin Infect Dis. 2019 Feb 1. doi: 10.1093/cid/ciz057. [Epub ahead of print] No abstract available.

PMID:
30715221
13.

Reply to Cheng and Chuang.

Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP.

Clin Infect Dis. 2019 Jan 30. doi: 10.1093/cid/ciz081. [Epub ahead of print] No abstract available.

PMID:
30715199
14.

Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic/Pharmacokinetic Model.

Kebriaei R, Rice SA, Stamper KC, Rybak MJ.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01743-18. doi: 10.1128/AAC.01743-18. Print 2019 Apr.

PMID:
30670436
15.

The Optimal Use of the Polymyxins Before Their Time Is Up.

Alosaimy S, Jorgensen SCJ, Rybak MJ.

Pharmacotherapy. 2019 Jan;39(1):7-9. doi: 10.1002/phar.2207. Epub 2019 Jan 8. No abstract available.

PMID:
30623457
16.

Risk Factors for Bloodstream Infections Among an Urban Population with Skin and Soft Tissue Infections: A Retrospective Unmatched Case-Control Study.

Rybak MJ, Zasowski EJ, Jorgensen SCJ, Lagnf AM, Davis SL, Mendelsohn AB, Margaritis V.

Infect Dis Ther. 2019 Mar;8(1):75-85. doi: 10.1007/s40121-018-0227-9. Epub 2018 Dec 18.

17.

Mutations in cdsA and pgsA Correlate with Daptomycin Resistance in Streptococcus mitis and S. oralis.

Tran TT, Mishra NN, Seepersaud R, Diaz L, Rios R, Dinh AQ, Garcia-de-la-Maria C, Rybak MJ, Miro JM, Shelburne SA, Sullam PM, Bayer AS, Arias CA.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01531-18. doi: 10.1128/AAC.01531-18. Print 2019 Feb.

PMID:
30509945
18.

Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closer.

Jorgensen SCJ, Lagnf AM, Bhatia S, Shamim MD, Rybak MJ.

J Antimicrob Chemother. 2019 Feb 1;74(2):489-498. doi: 10.1093/jac/dky452.

PMID:
30418557
19.

Making the change to area under the curve-based vancomycin dosing.

Heil EL, Claeys KC, Mynatt RP, Hopkins TL, Brade K, Watt I, Rybak MJ, Pogue JM.

Am J Health Syst Pharm. 2018 Dec 15;75(24):1986-1995. doi: 10.2146/ajhp180034. Epub 2018 Oct 17. No abstract available.

PMID:
30333114
20.

Pathogen-Specific Clinical Trials: A New Paradigm in Clinical Trials for Multidrug-Resistant Organisms.

Jorgensen SCJ, Rybak MJ.

Infect Dis Ther. 2018 Dec;7(4):401-405. doi: 10.1007/s40121-018-0215-0. Epub 2018 Oct 3. No abstract available.

21.

Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus.

Xhemali X, Smith JR, Kebriaei R, Rice SA, Stamper KC, Compton M, Singh NB, Jahanbakhsh S, Rybak MJ.

J Antimicrob Chemother. 2019 Jan 1;74(1):82-86. doi: 10.1093/jac/dky376.

PMID:
30260409
22.

Development of a Risk-Scoring Tool to Determine Appropriate Level of Care in Acute Bacterial Skin and Skin Structure Infections in an Acute Healthcare Setting.

Claeys KC, Zasowski EJ, Lagnf AM, Sabagha N, Levine DP, Davis SL, Rybak MJ.

Infect Dis Ther. 2018 Dec;7(4):495-507. doi: 10.1007/s40121-018-0212-3. Epub 2018 Sep 22.

23.

Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteraemia in a haemodialysis patient.

Jorgensen SCJ, McDonald P, Mynatt RP, Pogue JM, Lerner SA, Dhar S, Salimnia H, Rybak MJ.

J Antimicrob Chemother. 2018 Dec 1;73(12):3529-3531. doi: 10.1093/jac/dky346. No abstract available.

PMID:
30188993
24.

Pharmacodynamic Analysis of Daptomycin-Treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint.

Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP.

Clin Infect Dis. 2018 Sep 5. doi: 10.1093/cid/ciy749. [Epub ahead of print]

PMID:
30188976
25.

Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA.

Bhise K, Sau S, Kebriaei R, Rice SA, Stamper KC, Alsaab HO, Rybak MJ, Iyer AK.

Materials (Basel). 2018 Jul 20;11(7). pii: E1245. doi: 10.3390/ma11071245.

26.

Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus.

Singh NB, Yim J, Jahanbakhsh S, Sakoulas G, Rybak MJ.

Diagn Microbiol Infect Dis. 2018 Aug;91(4):363-370. doi: 10.1016/j.diagmicrobio.2018.03.020. Epub 2018 Apr 7.

PMID:
29807674
27.

Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Biofilm Model.

Jahanbakhsh S, Singh NB, Yim J, Rose WE, Rybak MJ.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00567-18. doi: 10.1128/AAC.00567-18. Print 2018 Aug.

28.

Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with β-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions.

Kebriaei R, Rice SA, Singh KV, Stamper KC, Dinh AQ, Rios R, Diaz L, Murray BE, Munita JM, Tran TT, Arias CA, Rybak MJ.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00315-18. doi: 10.1128/AAC.00315-18. Print 2018 Aug.

29.

Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties.

Jorgensen SCJ, Mercuro NJ, Davis SL, Rybak MJ.

Infect Dis Ther. 2018 Jun;7(2):197-217. doi: 10.1007/s40121-018-0198-x. Epub 2018 Mar 31. Review.

30.
31.

Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations.

Smith JR, Yim J, Rice S, Stamper K, Kebriaei R, Rybak MJ.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00101-18. doi: 10.1128/AAC.00101-18. Print 2018 May.

32.

Role of Vancomycin Minimum Inhibitory Concentrations by Modified Population Analysis Profile Method and Clinical Outcomes in High Inoculum Methicillin-Resistant Staphylococcus aureus Infections.

Trinh TD, Zasowski EJ, Claeys KC, Casapao AM, Compton M, Lagnf A, Kidambi SD, Levine DP, Rybak MJ.

Infect Dis Ther. 2018 Mar;7(1):161-169. doi: 10.1007/s40121-018-0187-0. Epub 2018 Feb 22.

33.

Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.

Jorgensen SCJ, Rybak MJ.

Pharmacotherapy. 2018 Apr;38(4):444-461. doi: 10.1002/phar.2092. Epub 2018 Mar 28. Review.

PMID:
29427523
34.

A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.

Beganovic M, Luther MK, Rice LB, Arias CA, Rybak MJ, LaPlante KL.

Clin Infect Dis. 2018 Jul 2;67(2):303-309. doi: 10.1093/cid/ciy064.

PMID:
29390132
35.

Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis.

Claeys KC, Zasowski EJ, Trinh TD, Lagnf AM, Davis SL, Rybak MJ.

Infect Dis Ther. 2018 Mar;7(1):135-146. doi: 10.1007/s40121-017-0179-5. Epub 2017 Nov 21.

36.

Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin.

Zasowski EJ, Murray KP, Trinh TD, Finch NA, Pogue JM, Mynatt RP, Rybak MJ.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01684-17. doi: 10.1128/AAC.01684-17. Print 2018 Jan.

37.

Genomic characterization of an extensively drug-resistant KPC-2-producing Klebsiella pneumoniae ST855 (CC258) only susceptible to ceftazidime-avibactam isolated in Brazil.

Aires CAM, Rybak MJ, Yim J, Pereira PS, Rocha-de-Souza CM, Albano RM, Cavalcanti VO, D'Alincourt Carvalho-Assef AP, Gomes MZR, Asensi MD.

Diagn Microbiol Infect Dis. 2017 Dec;89(4):324-327. doi: 10.1016/j.diagmicrobio.2017.08.017. Epub 2017 Aug 25.

38.

A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.

Finch NA, Zasowski EJ, Murray KP, Mynatt RP, Zhao JJ, Yost R, Pogue JM, Rybak MJ.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01293-17. doi: 10.1128/AAC.01293-17. Print 2017 Dec.

39.

Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: Prevalence and risk factors.

Trinh TD, Zasowski EJ, Claeys KC, Lagnf AM, Kidambi S, Davis SL, Rybak MJ.

Diagn Microbiol Infect Dis. 2017 Sep;89(1):61-66. doi: 10.1016/j.diagmicrobio.2017.06.009. Epub 2017 Jun 19.

PMID:
28716451
40.

Novel application of published risk factors for methicillin-resistant S. aureus in acute bacterial skin and skin structure infections.

Claeys KC, Zasowski EJ, Lagnf AM, Levine DP, Davis SL, Rybak MJ.

Int J Antimicrob Agents. 2018 Jan;51(1):43-46. doi: 10.1016/j.ijantimicag.2017.05.015. Epub 2017 Jun 28.

PMID:
28668679
41.

Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs).

Yim J, Smith JR, Singh NB, Rice S, Stamper K, Garcia de la Maria C, Bayer AS, Mishra NN, Miró JM, Tran TT, Arias CA, Sullam P, Rybak MJ.

J Antimicrob Chemother. 2017 Aug 1;72(8):2290-2296. doi: 10.1093/jac/dkx130.

42.

Role of Combination Antimicrobial Therapy for Vancomycin-Resistant Enterococcus faecium Infections: Review of the Current Evidence.

Yim J, Smith JR, Rybak MJ.

Pharmacotherapy. 2017 May;37(5):579-592. doi: 10.1002/phar.1922. Epub 2017 May 9. Review.

PMID:
28273381
43.

Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.

Garcia-de-la-Maria C, Xiong YQ, Pericas JM, Armero Y, Moreno A, Mishra NN, Rybak MJ, Tran TT, Arias CA, Sullam PM, Bayer AS, Miro JM.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02418-16. doi: 10.1128/AAC.02418-16. Print 2017 May.

44.

Perturbations of Phosphatidate Cytidylyltransferase (CdsA) Mediate Daptomycin Resistance in Streptococcus mitis/oralis by a Novel Mechanism.

Mishra NN, Tran TT, Seepersaud R, Garcia-de-la-Maria C, Faull K, Yoon A, Proctor R, Miro JM, Rybak MJ, Bayer AS, Arias CA, Sullam PM.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02435-16. doi: 10.1128/AAC.02435-16. Print 2017 Apr.

45.

Time-kill determination of the bactericidal activity of telavancin and vancomycin against clinical methicillin-resistant Staphylococcus aureus isolates from cancer patients.

Rolston KV, Wang W, Nesher L, Smith JR, Rybak MJ, Prince RA.

Diagn Microbiol Infect Dis. 2017 Apr;87(4):338-342. doi: 10.1016/j.diagmicrobio.2016.12.010. Epub 2016 Dec 16.

PMID:
28109549
46.

Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.

Navalkele B, Pogue JM, Karino S, Nishan B, Salim M, Solanki S, Pervaiz A, Tashtoush N, Shaikh H, Koppula S, Koons J, Hussain T, Perry W, Evans R, Martin ET, Mynatt RP, Murray KP, Rybak MJ, Kaye KS.

Clin Infect Dis. 2017 Jan 15;64(2):116-123. doi: 10.1093/cid/ciw709. Epub 2016 Oct 20.

PMID:
27986669
47.

Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.

Zasowski EJ, Trinh TD, Claeys KC, Casapao AM, Sabagha N, Lagnf AM, Klinker KP, Davis SL, Rybak MJ.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e02015-16. doi: 10.1128/AAC.02015-16. Print 2017 Feb.

48.

Acceptance of Pharmacist-Driven Antimicrobial Stewardship Recommendations With Differing Levels of Physician Involvement in a Children's Hospital.

Molloy L, McGrath E, Thomas R, Kaye KS, Rybak MJ.

Clin Pediatr (Phila). 2017 Jul;56(8):744-751. doi: 10.1177/0009922816678598. Epub 2016 Nov 20.

PMID:
27872355
49.

Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii.

Sakoulas G, Rose W, Berti A, Olson J, Munguia J, Nonejuie P, Sakoulas E, Rybak MJ, Pogliano J, Nizet V.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01745-16. doi: 10.1128/AAC.01745-16. Print 2017 Feb.

50.

β-Lactamase Inhibitors Enhance the Synergy between β-Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus.

Henson KE, Yim J, Smith JR, Sakoulas G, Rybak MJ.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01564-16. doi: 10.1128/AAC.01564-16. Print 2017 Jan.

Supplemental Content

Loading ...
Support Center